Influence of Doxycycline Use as Prophylaxis for Sexually Transmitted Infections on Bacterial Resistance and Gut Microbiota: MiDoxyR-PEP Study
Key facts
- Where
- aviles, León, Oviedo, Salamanca és Santander, SpanyolországSee the 5 sites
- Phase
- 4. fázis
Where in Spanyolország
- Hospital Universitario San Agustinaviles, SpanyolországTaking people
- Hospital Universitario De LeonLeón, SpanyolországTaking people
- Hospital Universitario Central De AsturiasOviedo, SpanyolországTaking people
- Hospital Universitario De SalamancaSalamanca, SpanyolországTaking people
- Hospital Universitario Marqués de ValdecillaSantander, SpanyolországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto De Investigacion Marques De Valdecilla
- Trial code
- EU 2025-525150-19-01
- Record updated
- 2026. november 4.
- Original description
To study the impact of post-exposure prophylaxis with doxycycline (doxyPEP) among MSM and transgender women on the incidence of nasal colonization by Staphylococcus aureus with resistance mechanisms, the incidence of sexually transmitted infections (STIs), and to assess changes in gut microbiota following the initiation of doxyPEP in this population.Read full original descriptionShow less
To study the impact of post-exposure prophylaxis with doxycycline (doxyPEP) among MSM and transgender women on the incidence of nasal colonization by Staphylococcus aureus with resistance mechanisms, the incidence of sexually transmitted infections (STIs), and to assess changes in gut microbiota following the initiation of doxyPEP in this population.
Inclusion: Adult patients (18 years of age or older) who are MSM and transgender women, PrEP users, or people living with HIV; Who have at least two of the following risk factors for contracting STIs, based on the recommendations of the Ministry of Health; More than 10 different sexual partners in the past year; Engaging in anal sex without a condom at least once in the past year; Drug use associated with having unprotected sex at least once in the past year; Administration of post-exposure prophylaxis on more than one occasion in the past year; Informed Consent Form.
Exclusion: Patients who are receiving long-term antimicrobial therapy, other than antiretroviral therapy or prophylaxis; PrEP users who have been on treatment for less than 3 months, or people living with HIV who have a detectable viral load or have been on active antiretroviral therapy for less than 3 months; Patients with an allergy or intolerance to tetracyclines; Patients under the age of 18; Participation in another study involving the use of antimicrobials.